查看購物車
  • English
  • Japanese
  • Korean
全球醫藥和生技領域穿戴式裝置市場：按產品、治療領域、應用、最終用戶和地區分類－預測至2031年
市場調查報告書
商品編碼
2031737

全球醫藥和生技領域穿戴式裝置市場：按產品、治療領域、應用、最終用戶和地區分類－預測至2031年

Wearables in Pharma & Biotech Market by Product, Therapy, Application, End User - Global Forecasts to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 401 Pages | 訂單完成後即時交付

價格

預計到 2031 年，醫藥和生技領域穿戴式裝置的市場規模將達到 99.7 億美元，而 2026 年為 39.8 億美元，複合年成長率為 20.2%。

生物感測器、小型化和數位化領域的快速技術進步正在推動穿戴式裝置市場的發展。全球數位連結的改善也是支撐穿戴式裝置市場擴張的關鍵因素。根據電訊（ITU）統計，到2023年，全球已有超過54億人上網。這種廣泛的網路連接使得將穿戴式裝置的資料無縫整合到雲端環境中成為可能。

調查範圍
調查期 2024-2031
基準年 2025
預測期 2025-2031
目標單元 金額（10億美元）
部分 按產品、處理區域、應用、最終用戶、地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

此外，「我們所有人」（All of Us）研究計畫已招募超過50萬名參與者，其中一些參與者透過穿戴式裝置提供活動量、心率和睡眠模式等數據。這反映出穿戴式科技在大規模生物醫學研究和精準醫療中的作用日益增強。遠端患者監護（RPM）和數位化醫療解決方案的日益普及進一步推動了這一成長。在美國，醫療保險和醫療補助服務中心（CMS）報告稱，自2022年政策擴展以來，遠距生理監測服務的報銷申請顯著增加。這表明醫療保健提供者正在廣泛採用穿戴式裝置輔助的醫療服務。此外，感測器精度和多參數監測技術的進步使得穿戴式裝置能夠測量除基本生命徵像之外的具有臨床意義的終點指標。這正在拓展穿戴式裝置在藥物安全性和治療研究的應用範圍。

醫藥和生物技術市場中的穿戴式設備-IMG1

“按產品類別分類，持續血糖監測（CGM）產品佔據最大的市場佔有率。”

產品類別包括智慧型手錶、健身手環、智慧戒指、持續血糖監測儀 (CGM)、貼片、穿戴式注射器等。由於臨床指南的大力支持、不斷擴大的患者群體以及與先進糖尿病管理系統的兼容性，CGM 佔據了較大的市場佔有率。美國糖尿病協會 (ADA) 基於 2024 年護理標準，建議更多醣尿病患者使用 CGM，這進一步擴大了市場規模。此外，英國國家食品藥物管理局體系 (NHS) 為數十萬名患者提供的報銷計畫也促進了該地區的市場成長。同時，美國食品藥物管理局 (FDA)核准了可與胰島素輸注系統配合使用的互通 CGM，也推動了該地區的市場成長。這些設備每天最多可測量 288 次血糖值，因此在市場上具有極高的價值。

“按最終用戶分類，預計到 2025 年，製藥和生物技術公司將佔據最大的市場佔有率。”

預計到2025年，製藥和生技公司將在醫藥和生技領域的穿戴式裝置市場佔據主導地位。這主要是由於臨床試驗日益複雜，需要穿戴式技術進行資料收集。根據塔夫茨藥物研發研究中心的研究，目前的臨床試驗方案平均包含20個或更多終點指標，進一步增加了資料收集的需求。在此背景下，穿戴式科技的應用正在迅速擴展。此外，英國生物銀行等大規模研究舉措已成功利用穿戴式科技收集了超過10萬名受試者的數據，凸顯了穿戴式科技在藥物研究中的巨大潛力。鑑於這些情況，預計製藥和生物技術公司仍將是該市場的主要終端用戶。

“預計亞太地區在預測期內將錄得最高的成長率。”

亞太地區在醫藥和生技市場的穿戴式裝置領域中保持著最高的成長率。這一成長歸因於多種因素，包括數位醫療基礎設施的改善、臨床研究活動的增加以及大量患者無法獲得充足的醫療保健服務。世界衛生組織指出，西太平洋和東南亞地區合計佔全球疾病負擔的很大一部分。電訊（ITU）的數據顯示，近年來亞太地區的網路普及率已超過66%至70%。此外，中國和印度等國家正在崛起為臨床試驗中心，目前已確認在這些地區進行數千項試驗。相關技術正在被引入，以簡化這些臨床試驗的流程。 2024年9月，Biobeat宣布透過與Infinity Pharma的合作，將業務拓展至阿根廷和智利。

Abbott（美國）、Dexcom, Inc.（美國）和 Masimo（美國）是製藥和生物技術領域穿戴式裝置的一些領先公司。

  • 本研究對醫藥和生技市場中穿戴式科技領域的關鍵參與者進行了詳細的競爭分析，包括公司簡介、近期發展和主要市場策略。

調查範圍

本研究報告從產品、治療領域、應用、終端用戶和地區等維度分析了醫藥和生物技術領域的穿戴式設備市場。報告詳細闡述了影響醫藥和生物技術領域穿戴式裝置成長的關鍵因素，包括促進因素、限制因素、挑戰和機會。報告深入分析了主要行業參與企業，提供了關於其業務概況、詳細資訊方案、服務、關鍵戰略、協議、夥伴關係關係、新產品和服務推出、併購醫藥和生物技術領域穿戴式設備相關最新趨勢的見解。此外，報告還對市場生態系統中新興的新創公司進行了競爭分析。

購買本報告的理由

本報告透過提供關於穿戴式裝置及其細分市場銷售額的最準確預測，幫助醫藥和生技市場的市場領導和新參與企業。它幫助相關人員了解競爭格局，更好地定位自身業務，並制定合適的打入市場策略。此外，它還幫助相關人員了解市場趨勢，並提供有關關鍵市場促進因素、限制因素、挑戰和機會的資訊。

本報告深入分析了以下幾點：

  • 本研究分析了影響製藥和生物技術領域穿戴式設備成長的因素，包括關鍵促進因素（向以價值為基礎和以患者為中心的醫療保健模式轉變、需要持續病患監測的慢性病患病率不斷上升、醫療保健的快速數位化以及遠端醫療服務的擴展）、阻礙因素（醫療遠端患者監護提供者的高部署和整合成本、對數據隱私和居家照護保健的IT 系統的互通性有限、病患接受率低以及數位素養障礙）。
  • 產品開發與創新：深入洞察醫藥與生技市場穿戴式裝置領域未來的技術趨勢、研發活動以及新產品/服務的推出。
  • 市場發展：提供盈利市場的全面資訊。本報告分析了不同地區製藥和生物技術領域的穿戴式設備。
  • 市場多元化：全面介紹醫藥和生技市場中穿戴科技領域的新產品和服務、未開發的市場、近期趨勢和投資情況。
  • 競爭分析：對製藥和生物技術市場中穿戴式科技領域的主要參與者（包括 BD（美國）、雅培（美國）、Masimo（美國）、DexCom, Inc.（美國）和美敦力（愛爾蘭））的市場佔有率、成長策略和服務產品進行詳細評估。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 相互關聯的市場與跨產業機遇
  • 一級/二級/三級公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
  • 總體經濟指標
  • 供應鏈分析
  • 生態系分析
  • 價格分析
  • 貿易分析
  • 2026-2027 年主要會議和活動
  • 影響客戶業務的趨勢/顛覆性因素
  • 投資和資金籌措場景
  • 案例研究分析
  • 美國關稅在2025年的影響

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 主要技術
  • 互補技術
  • 相鄰技術
  • 技術/產品藍圖
  • 專利分析
  • 未來應用
  • 人工智慧/通用人工智慧的影響

第7章 監理情勢

  • 當地法規和合規性
    • 監管機構、政府機構和其他組織
    • 業界標準

第8章：顧客趨勢與購買行為

  • 決策流程
  • 採購過程中的關鍵相關人員及其評估標準
  • 實施障礙和內部挑戰
  • 終端用戶產業未滿足的需求
  • 市場盈利

第9章：醫藥和生技領域的穿戴式裝置市場（依產品分類）

  • 智慧型手錶
  • 健身手環
  • 智慧戒指
  • 連續血糖監測儀
  • 修補
  • 穿戴式注射器
  • 其他

第10章：製藥和生技領域的穿戴式裝置市場（按治療領域分類）

  • 心血管系統
  • 腫瘤學

第11章：醫藥和生技領域的穿戴式裝置市場（按應用領域分類）

  • 藥物發現
  • 臨床試驗
  • 藥物依從性和行為支持
  • 慢性病監測
  • 個人化和預防性數位療法

第12章：製藥和生技領域的穿戴式裝置市場（依最終用戶分類）

  • 製藥和生物技術公司
  • 醫療保健專業人員和臨床醫生
  • 受託研究機構
  • 其他

第13章：醫藥和生技領域的穿戴式裝置市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • GCC
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其餘海灣合作理事會國家
    • 南非
    • 其他

第14章 競爭格局

  • 概述
  • 主要參與企業的策略/優勢，2023-2026 年
  • 2021-2025年收入分析
  • 2025年市佔率分析
  • 品牌/產品對比
  • 企業估值和財務指標
  • 企業估值矩陣：主要公司，2025 年
  • 公司估值矩陣：新創企業/中小企業，2025 年
  • 競爭格局

第15章：公司簡介

  • 主要參與企業
    • DEXCOM, INC.
    • ABBOTT
    • MASIMO
    • BD
    • APPLE INC.
    • BOSTON SCIENTIFIC CORPORATION
    • IRHYTHM TECHNOLOGIES, INC.
    • KONINKLIJKE PHILIPS NV
    • MEDTRONIC
    • BIOINTELLISENSE, INC.
    • F. HOFFMANN-LA ROCHE LTD
    • GE HEALTHCARE
    • BIOBEAT
    • EMPATICA INC.
    • VITALCONNECT
    • AMETRIS, LLC
    • ALIVECOR, INC.
    • WITHINGS
    • VIVALNK, INC.
    • MEDIBIOSENSE
  • 其他公司
    • SIBEL HEALTH, INC.
    • BYTEFLIES
    • STRADOS LABS
    • ONERA TECHNOLOGIES BV
    • EPICORE BIOSYSTEMS, INC.

第16章調查方法

第17章附錄

Product Code: HIT 10410

The wearables in pharma & biotech market is projected to reach USD 9.97 billion by 2031 from USD 3.98 billion in 2026, at a CAGR of 20.2%. The market is driven by rapid technological developments in biosensors, miniaturization, and digitization. Increasing global digital connectivity is another significant facilitator of the expanding wearable market. The International Telecommunication Union reported that over 5.4 billion people worldwide were using the internet in 2023. This widespread connectivity is enabling the seamless integration of data from wearable devices into cloud environments.

Scope of the Report
Years Considered for the Study2024-2031
Base Year2025
Forecast Period2025-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Therapeutic Area, Application, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Additionally, the All of Us Research Program has recruited more than 500,000 participants, some of whom are contributing data from wearables, including activity levels, heart rate, and sleep patterns. This reflects the growing role of wearable technology in large-scale biomedical research and precision medicine. This growth is further supported by the increasing adoption of remote patient monitoring (RPM) and digital care solutions. In the US, the Centers for Medicare & Medicaid Services reported a substantial increase in reimbursement claims for remote physiological monitoring services following the expansion of the policy in 2022. This indicates widespread adoption of wearable-derived care among healthcare providers. In addition, developments in the accuracy of sensors and multi-parameter monitoring are allowing wearables to measure clinically significant endpoints beyond basic vital signs. This is expanding the scope of wearables in drug safety and therapeutic studies.

Wearables in Pharma & Biotech Market - IMG1

"By product, continuous glucose monitors (CGMs) segment to account for largest market share"

The product segment is divided into smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), patches, wearable injectors, and others. The CGMs segment has a large market share due to the high level of support from clinical guidelines, increasing scope of eligible patients, and the ability of the devices to be used with the most advanced diabetic management systems. The American Diabetes Association recommends the use of CGMs for a broad population of diabetic patients, as per the 2024 Standards of Care, thereby increasing the scope of the market. Furthermore, the availability of reimbursement schemes for hundreds of thousands of patients through the National Health Service has also helped the market expand in the region. In addition, approvals by the Food and Drug Administration for interoperable CGMs used in conjunction with insulin delivery systems have also helped the market expand in the region. The devices also provide up to 288 glucose readings in a day, making them highly valuable in the market .

"By end user, pharmaceutical and biotech companies accounted for largest market share in 2025"

Pharmaceutical and biotech companies dominated the market for wearables in the pharma & biotech market in terms of market share in 2025. This is mainly attributed to the complexity of clinical trials, where pharmaceutical and biotech companies require wearable technologies for data collection. According to a study by the Tufts Center for the Study of Drug Development, clinical trial protocols currently involve more than 20 endpoints on average, thus increasing the requirement for data collection. Wearable technologies are increasingly being used in this context. Furthermore, large-scale research initiatives, such as the UK Biobank, have successfully used wearable technologies for data collection from over 100,000 individuals, thus highlighting the potential of wearable technologies in pharmaceutical research. Considering this, pharmaceutical and biotech companies are likely to remain a dominant end user in this market .

"Asia Pacific to witness highest growth rate during forecast period"

The Asia Pacific (APAC) region is experiencing the highest growth rate in the wearables in pharma & biotech market. This growth can be attributed to several factors, including improvements in digital health infrastructure, a rise in clinical research activities, and a significant number of underserved patients. According to the WHO, the combined Western Pacific and Southeast Asia regions contribute a large share to the world's disease burden. It has been mentioned by the International Telecommunication Union that the penetration of the Internet in the APAC region has surpassed 66% to 70% in recent years. Additionally, it has been observed that countries like China and India are emerging as hubs for clinical trials, with thousands of trials already conducted in these regions. Technology is being adopted to enhance the efficiency of these trials. In September 2024, Biobeat announced its expansion into Argentina and Chile through a partnership with Infinity Pharma.

The breakdown of primary participants is as given below:

  • By Company Type - Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%
  • By Designation - C-level: 30%, Director-level: 50%, and Others: 20%
  • By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the World: 10%.

Abbott (US), Dexcom, Inc. (US), and Masimo (US) are some of the key players in the wearables in pharma & biotech market.

  • The study includes an in-depth competitive analysis of these key players in the wearables in pharma & biotech market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the wearables in pharma & biotech market by Product (Smartwatches, Fitness Bands, Smart Rings, Continuous Glucose Monitors (CGM), Patches, Wearable Injectors, Others), Therapeutic Area (cardiovascular (atherosclerotic cardiovascular disease (ASCVD) / secondary prevention, heart failure (HFREF and HFPEF), hypertension, atrial fibrillation (AF) / stroke prevention, pulmonary hypertension, structural heart disease / interventional cardiology), oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders / pain management, women's health & reproductive health, other diseases), Application (drug discovery, clinical trials (phase ii, phase iii, phase iv), medication adherence & behavioral support, chronic disease monitoring, personalized & preventive digital therapeutics), end user (pharmaceutical & biotech companies, healthcare providers & clinicians, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the wearables in pharma & biotech market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the wearables in pharma & biotech market. Competitive analysis of upcoming startups in the market ecosystem is covered in this report.

Reasons to Buy this Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the wearables in pharma & biotech market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Shift toward value-based and patient-centric healthcare models, Rising prevalence of chronic diseases requiring continuous patient monitoring, Rapid digitalization of healthcare and expansion of telehealth services) restraints (High implementation and integration costs for healthcare providers, Data privacy and cybersecurity concerns) opportunities (Expansion of remote patient monitoring and home-based care models, Integration of advanced analytics and personalized healthcare) and challenges (Interoperability limitations with existing healthcare IT systems, Low patient adoption and digital literacy barriers) influencing the growth of the wearables in pharma & biotech market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the wearables in pharma & biotech market
  • Market Development: Comprehensive information about lucrative markets; the report analyses the wearables in pharma & biotech market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the wearables in pharma & biotech market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like BD (US), Abbott (US), Masimo (US), DexCom, Inc. (US), Medtronic (Ireland), among others, in the wearables in pharma & biotech market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 UNIT CONSIDERED
  • 1.6 STAKEHOLDERS

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING WEARABLES IN PHARMA & BIOTECH MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 ATTRACTIVE OPPORTUNITIES FOR WEARABLES IN PHARMA & BIOTECH MARKET
  • 3.2 NORTH AMERICA WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER AND COUNTRY
  • 3.3 WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Shift toward value-based and patient-centric healthcare models
      • 4.2.1.2 Prevalence of chronic diseases requiring continuous patient monitoring
      • 4.2.1.3 Rapid digitalization of healthcare and expansion of telehealth services
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High implementation and integration costs
      • 4.2.2.2 Data privacy and cybersecurity concerns
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expansion of remote patient monitoring and home-based care models
      • 4.2.3.2 Integration of advanced analytics and personalized healthcare
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Limited interoperability with existing healthcare IT systems
      • 4.2.4.2 Low patient adoption and digital literacy barriers
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE)
    • 5.1.2 BARGAINING POWER OF BUYERS (MODERATE TO HIGH)
    • 5.1.3 THREAT OF SUBSTITUTES (LOW TO MODERATE)
    • 5.1.4 THREAT OF NEW ENTRANTS (MODERATE)
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH)
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 GDP TRENDS AND FORECAST
    • 5.2.2 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY PRODUCT, 2025
    • 5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025
  • 5.6 TRADE ANALYSIS
    • 5.6.1 IMPORT DATA (HS CODE 9018)
    • 5.6.2 EXPORT DATA (HS CODE 9018)
  • 5.7 KEY CONFERENCES AND EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.9 INVESTMENT AND FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
  • 5.11 IMPACT OF 2025 US TARIFF
    • 5.11.1 KEY TARIFF RATES
    • 5.11.2 PRICE IMPACT ANALYSIS
    • 5.11.3 IMPACT ON COUNTRIES/REGIONS
      • 5.11.3.1 US
      • 5.11.3.2 Europe
      • 5.11.3.3 Asia Pacific
    • 5.11.4 IMPACT ON END-USE INDUSTRIES
      • 5.11.4.1 Pharmaceutical & biotech companies
      • 5.11.4.2 Healthcare providers & clinicians
      • 5.11.4.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY TECHNOLOGIES
    • 6.1.1 ADVANCED BIOSENSING AND MULTI-PARAMETER WEARABLES
    • 6.1.2 AI-DRIVEN ANALYTICS AND CLINICAL INTELLIGENCE
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 MOBILE HEALTH AND REMOTE PATIENT MONITORING
    • 6.2.2 ANALYTICS AND POPULATION-LEVEL HEALTH DATA INTEGRATION
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 INTERNET OF MEDICAL THINGS AND CONNECTED DEVICES
    • 6.3.2 CLOUD AND EDGE COMPUTING
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 PATENT PUBLICATION TRENDS
    • 6.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 6.6 FUTURE APPLICATIONS
    • 6.6.1 AI-DRIVEN PREDICTIVE MONITORING AND CLINICAL DECISION SUPPORT
    • 6.6.2 CLOSED-LOOP THERAPEUTIC AND DRUG DELIVERY SYSTEMS
    • 6.6.3 DECENTRALIZED AND HYBRID CLINICAL TRIAL ENABLEMENT
    • 6.6.4 CONTINUOUS DISEASE MANAGEMENT AND PREVENTIVE HEALTHCARE
    • 6.6.5 ADVANCED BIOSENSING AND NON-INVASIVE DIAGNOSTICS
    • 6.6.6 INTEGRATION WITH DIGITAL THERAPEUTICS AND PERSONALIZED MEDICINE
  • 6.7 IMPACT OF AI/GEN AI
    • 6.7.1 MARKET POTENTIAL OF AI/GEN AI
    • 6.7.2 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
      • 6.7.2.1 AI-driven continuous glucose monitoring and diabetes management at Dexcom
    • 6.7.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 6.7.3.1 Wearable data analytics and AI-driven monitoring platforms
      • 6.7.3.2 Digital health platforms, integration, and regulatory infrastructure
      • 6.7.3.3 Clinical care, remote monitoring, and personalized therapeutics
    • 6.7.4 USER READINESS AND IMPACT ASSESSMENT
      • 6.7.4.1 User readiness
        • 6.7.4.1.1 User A: Hospitals, clinics, and long-term care providers
        • 6.7.4.1.2 User B: Pharma and biotech companies
      • 6.7.4.2 Impact assessment
        • 6.7.4.2.1 User A: Hospitals, clinics, and long-term care providers
          • 6.7.4.2.1.1 Implementation
          • 6.7.4.2.1.2 Impact
        • 6.7.4.2.2 User B: Pharma and biotech companies
          • 6.7.4.2.2.1 Implementation
          • 6.7.4.2.2.2 Impact

7 REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM END-USE INDUSTRIES
    • 8.4.1 UNMET NEEDS
    • 8.4.2 END-USER EXPECTATIONS
  • 8.5 MARKET PROFITABILITY

9 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 SMARTWATCHES
    • 9.2.1 EXPANDING ROLE IN DIGITAL CLINICAL TRIALS AND REMOTE MONITORING
  • 9.3 FITNESS BANDS
    • 9.3.1 EMPHASIS ON REAL-WORLD EVIDENCE AND PATIENT-CENTRIC TRIAL DESIGNS
  • 9.4 SMART RINGS
    • 9.4.1 EMERGING CLINICAL-GRADE WEARABLES ENABLING EARLY DISEASE DETECTION AND CONTINUOUS MONITORING
  • 9.5 CONTINUOUS GLUCOSE MONITORS
    • 9.5.1 TRANSFORMING METABOLIC RESEARCH THROUGH REAL-TIME, HIGH-FREQUENCY DATA
  • 9.6 PATCHES
    • 9.6.1 CONTINUOUS, CLINICAL-GRADE MONITORING DRIVING ADOPTION IN DECENTRALIZED TRIALS
  • 9.7 WEARABLE INJECTORS
    • 9.7.1 GROWING DEMAND FOR SELF-ADMINISTRATION OF BIOLOGICS IN CHRONIC DISEASE MANAGEMENT
  • 9.8 OTHER PRODUCTS

10 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA

  • 10.1 INTRODUCTION
  • 10.2 CARDIOVASCULAR
    • 10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION
      • 10.2.1.1 Focus on improving endpoint capture and long-term outcomes monitoring
    • 10.2.2 HEART FAILURE
      • 10.2.2.1 Continuous physiologic monitoring and AI-enabled decompensation prediction
    • 10.2.3 HYPERTENSION
      • 10.2.3.1 Cuffless monitoring and AI-driven adherence management enabling precision blood pressure control
    • 10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION
      • 10.2.4.1 Rapid expansion of AI-powered arrhythmia detection algorithms and regulatory-cleared wearable ECG technologies
    • 10.2.5 PULMONARY HYPERTENSION
      • 10.2.5.1 Growing use of wearable-enabled remote monitoring and AI analytics to generate objective, real-world functional endpoints
    • 10.2.6 STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY
      • 10.2.6.1 Wearable-enabled remote recovery monitoring and procedural optimization supporting precision structural heart care
  • 10.3 ONCOLOGY
    • 10.3.1 SOLID TUMORS
      • 10.3.1.1 BREAST CANCER
        • 10.3.1.1.1 Continuous wearable-based survivorship monitoring and decentralized oncology trials driving personalized long-term care models
      • 10.3.1.2 LUNG CANCER
        • 10.3.1.2.1 Constant respiratory monitoring and decentralized trial adoption
      • 10.3.1.3 PROSTATE CANCER
        • 10.3.1.3.1 Expansion of decentralized oncology trials and long-term survivorship management
      • 10.3.1.4 COLORECTAL CANCER
        • 10.3.1.4.1 Increasing adoption of decentralized oncology trials and remote post-surgical monitoring
      • 10.3.1.5 BRAIN TUMOR
        • 10.3.1.5.1 Remote neurologic surveillance and functional recovery tracking accelerating personalized care
      • 10.3.1.6 OTHER SOLID TUMORS
    • 10.3.2 HEMATOLOGIC MALIGNANCIES
      • 10.3.2.1 LEUKEMIA
        • 10.3.2.1.1 Wearable-enabled infection surveillance and treatment resilience monitoring transforming outpatient care
      • 10.3.2.2 LYMPHOMA
        • 10.3.2.2.1 Shift toward outpatient infusion centers, home-based recovery, and decentralized clinical trials
      • 10.3.2.3 MULTIPLE MYELOMA
        • 10.3.2.3.1 Real-time toxicity and mobility tracking using wearables in long-term management
      • 10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES
    • 10.3.3 DIABETES
      • 10.3.3.1 Critical need for long-term, real-world metabolic monitoring
    • 10.3.4 MENTAL HEALTH & BEHAVIORAL HEALTH
      • 10.3.4.1 Rising global burden of psychiatric disorders
    • 10.3.5 RESPIRATORY DISORDERS
      • 10.3.5.1 Early exacerbation detection through continuous monitoring reduces hospitalization
    • 10.3.6 LIFESTYLE & WELLNESS IMPROVEMENT
      • 10.3.6.1 Continuous tracking for lifestyle optimization and preventive health risk management
    • 10.3.7 NEUROLOGY
      • 10.3.7.1 Wearable-based monitoring of neurological function and digital clinical endpoints in CNS disorders
    • 10.3.8 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT
      • 10.3.8.1 Wearable-guided functional movement and chronic pain monitoring in musculoskeletal disorders
    • 10.3.9 WOMEN'S HEALTH & REPRODUCTIVE HEALTH
      • 10.3.9.1 Continuous physiological and reproductive cycle using wearables
    • 10.3.10 OTHER DISEASES

11 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION

  • 11.1 INTRODUCTION
  • 11.2 DRUG DISCOVERY
    • 11.2.1 RECENT ADVANCES PROMOTE DISCOVERY OF DRUGS THROUGH WEARABLES IN PHARMA & BIOTECH
  • 11.3 CLINICAL TRIALS
    • 11.3.1 PHASE II
      • 11.3.1.1 AI-enabled remote monitoring and adaptive trial designs accelerate adoption
    • 11.3.2 PHASE III
      • 11.3.2.1 Rapid expansion of decentralized and hybrid global trial models propels growth
    • 11.3.3 PHASE IV
      • 11.3.3.1 Ability to improve patient engagement and retention in long-duration studies drives market
  • 11.4 MEDICATION ADHERENCE & BEHAVIORAL SUPPORT
    • 11.4.1 CONNECTED REMINDERS, PASSIVE MONITORING, AND PERSONALIZED NUDGES BOOST ADOPTION
  • 11.5 CHRONIC DISEASE MONITORING
    • 11.5.1 CONTINUOUS PHYSIOLOGICAL TRACKING AND PROACTIVE INTERVENTION CAPABILITIES INCREASE ADOPTION
  • 11.6 PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS
    • 11.6.1 BIOMETRIC SENSING AND AI-DRIVEN COACHING RAISE DEMAND FOR WEARABLES

12 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER

  • 12.1 INTRODUCTION
  • 12.2 PHARMACEUTICAL & BIOTECH COMPANIES
    • 12.2.1 CLINICAL DIGITIZATION, REAL-WORLD EVIDENCE GENERATION, AND CONNECTED THERAPY MODELS DRIVE MARKET
  • 12.3 HEALTHCARE PROVIDERS & CLINICIANS
    • 12.3.1 REMOTE PATIENT MONITORING, PREVENTIVE CARE, AND DATA-DRIVEN CLINICAL DECISION SUPPORT BOOST GROWTH
  • 12.4 CONTRACT RESEARCH ORGANIZATIONS
    • 12.4.1 DECENTRALIZED TRIALS, WEARABLE DATA INTEGRATION, AND FASTER CLINICAL EXECUTION RAISE DEMAND
  • 12.5 OTHER END USERS

13 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION

  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    • 13.2.1 US
      • 13.2.1.1 High concentration of clinical research activity, clinical trial inefficiencies, and cost pressures to drive market
    • 13.2.2 CANADA
      • 13.2.2.1 Clinical research participation, public health burden, and digital health adoption to drive market
  • 13.3 EUROPE
    • 13.3.1 GERMANY
      • 13.3.1.1 Expanding clinical trial activity and regulatory leadership to drive market
    • 13.3.2 FRANCE
      • 13.3.2.1 Regulatory-first approach to healthcare and clinical innovation to drive market
    • 13.3.3 UK
      • 13.3.3.1 Real-world data integration and decentralized trial innovation to drive market
    • 13.3.4 ITALY
      • 13.3.4.1 Evolving clinical trial landscape and regulatory decentralization to drive market
    • 13.3.5 SPAIN
      • 13.3.5.1 Increasing investment in digital health infrastructure to drive market
    • 13.3.6 REST OF EUROPE
  • 13.4 ASIA PACIFIC
    • 13.4.1 CHINA
      • 13.4.1.1 Clinical trial expansion and real-world data integration to drive market
    • 13.4.2 JAPAN
      • 13.4.2.1 Late-stage trial leadership and regulatory precision to drive market
    • 13.4.3 INDIA
      • 13.4.3.1 High-volume Phase III trial ecosystem and ABDM-driven digital health integration to drive market
    • 13.4.4 AUSTRALIA
      • 13.4.4.1 Early-phase trial leadership and remote care needs to drive market
    • 13.4.5 SOUTH KOREA
      • 13.4.5.1 Integrated clinical trial ecosystem and national health data infrastructure to drive market
    • 13.4.6 REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    • 13.5.1 BRAZIL
      • 13.5.1.1 Clinical trial leadership and high diabetes burden to drive market
    • 13.5.2 MEXICO
      • 13.5.2.1 Regulatory reforms and Phase III trial expansion to drive market
    • 13.5.3 REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 GCC
    • 13.6.2 SAUDI ARABIA
      • 13.6.2.1 Vision 2030-led digital health transformation to drive market
    • 13.6.3 UAE
      • 13.6.3.1 Digital health strategy, clinical trial expansion, and high healthcare investment to drive market
    • 13.6.4 REST OF GCC
    • 13.6.5 SOUTH AFRICA
      • 13.6.5.1 Clinical trial leadership and decentralized care models to drive market
    • 13.6.6 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

  • 14.1 OVERVIEW
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
  • 14.3 REVENUE ANALYSIS, 2021-2025
  • 14.4 MARKET SHARE ANALYSIS, 2025
  • 14.5 BRAND/PRODUCT COMPARISON
  • 14.6 COMPANY VALUATION AND FINANCIAL METRICS
  • 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 14.7.1 STARS
    • 14.7.2 EMERGING LEADERS
    • 14.7.3 PERVASIVE PLAYERS
    • 14.7.4 PARTICIPANTS
    • 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 14.7.5.1 Company footprint
      • 14.7.5.2 Region footprint
      • 14.7.5.3 Product footprint
      • 14.7.5.4 Therapeutic area footprint
      • 14.7.5.5 Application footprint
      • 14.7.5.6 End user footprint
  • 14.8 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025
    • 14.8.1 PROGRESSIVE COMPANIES
    • 14.8.2 RESPONSIVE COMPANIES
    • 14.8.3 DYNAMIC COMPANIES
    • 14.8.4 STARTING BLOCKS
    • 14.8.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2025
      • 14.8.5.1 List of start-ups/SMEs
      • 14.8.5.2 Competitive benchmarking of start-ups/SMEs
  • 14.9 COMPETITIVE SCENARIO
    • 14.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 14.9.2 DEALS
    • 14.9.3 OTHER DEVELOPMENTS

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
    • 15.1.1 DEXCOM, INC.
      • 15.1.1.1 Business overview
      • 15.1.1.2 Products offered
      • 15.1.1.3 Recent developments
        • 15.1.1.3.1 Product launches and approvals
        • 15.1.1.3.2 Deals
      • 15.1.1.4 MnM view
        • 15.1.1.4.1 Right to win
        • 15.1.1.4.2 Strategic choices
        • 15.1.1.4.3 Weaknesses and competitive threats
    • 15.1.2 ABBOTT
      • 15.1.2.1 Business overview
      • 15.1.2.2 Products offered
      • 15.1.2.3 Recent developments
        • 15.1.2.3.1 Product launches and approvals
        • 15.1.2.3.2 Deals
        • 15.1.2.3.3 Other developments
      • 15.1.2.4 MnM view
        • 15.1.2.4.1 Right to win
        • 15.1.2.4.2 Strategic choices
        • 15.1.2.4.3 Weaknesses and competitive threats
    • 15.1.3 MASIMO
      • 15.1.3.1 Business overview
      • 15.1.3.2 Products offered
      • 15.1.3.3 Recent developments
        • 15.1.3.3.1 Product launches and approvals
        • 15.1.3.3.2 Deals
      • 15.1.3.4 MnM view
        • 15.1.3.4.1 Right to win
        • 15.1.3.4.2 Strategic choices
        • 15.1.3.4.3 Weaknesses and competitive threats
    • 15.1.4 BD
      • 15.1.4.1 Business overview
      • 15.1.4.2 Products offered
      • 15.1.4.3 Recent developments
        • 15.1.4.3.1 Product launches and approvals
        • 15.1.4.3.2 Deals
      • 15.1.4.4 MnM view
        • 15.1.4.4.1 Right to win
        • 15.1.4.4.2 Strategic choices
        • 15.1.4.4.3 Weaknesses and competitive threats
    • 15.1.5 APPLE INC.
      • 15.1.5.1 Business overview
      • 15.1.5.2 Products offered
      • 15.1.5.3 Recent developments
        • 15.1.5.3.1 Product launches and approvals
        • 15.1.5.3.2 Deals
      • 15.1.5.4 MnM view
        • 15.1.5.4.1 Right to win
        • 15.1.5.4.2 Strategic choices
        • 15.1.5.4.3 Weaknesses and competitive threats
    • 15.1.6 BOSTON SCIENTIFIC CORPORATION
      • 15.1.6.1 Business overview
      • 15.1.6.2 Products offered
      • 15.1.6.3 Recent developments
        • 15.1.6.3.1 Deals
    • 15.1.7 IRHYTHM TECHNOLOGIES, INC.
      • 15.1.7.1 Business overview
      • 15.1.7.2 Products offered
      • 15.1.7.3 Recent developments
        • 15.1.7.3.1 Product launches and approvals
        • 15.1.7.3.2 Deals
    • 15.1.8 KONINKLIJKE PHILIPS N.V.
      • 15.1.8.1 Business overview
      • 15.1.8.2 Products offered
      • 15.1.8.3 Recent developments
        • 15.1.8.3.1 Product launches and approvals
        • 15.1.8.3.2 Deals
        • 15.1.8.3.3 Other developments
    • 15.1.9 MEDTRONIC
      • 15.1.9.1 Business overview
      • 15.1.9.2 Products offered
      • 15.1.9.3 Recent developments
        • 15.1.9.3.1 Deals
    • 15.1.10 BIOINTELLISENSE, INC.
      • 15.1.10.1 Business overview
      • 15.1.10.2 Products offered
      • 15.1.10.3 Recent developments
        • 15.1.10.3.1 Product launches and approvals
        • 15.1.10.3.2 Deals
    • 15.1.11 F. HOFFMANN-LA ROCHE LTD
      • 15.1.11.1 Business overview
      • 15.1.11.2 Products offered
      • 15.1.11.3 Recent developments
        • 15.1.11.3.1 Product launches and approvals
    • 15.1.12 GE HEALTHCARE
      • 15.1.12.1 Business overview
      • 15.1.12.2 Products offered
      • 15.1.12.3 Recent developments
        • 15.1.12.3.1 Product launches and approvals
        • 15.1.12.3.2 Deals
    • 15.1.13 BIOBEAT
      • 15.1.13.1 Business overview
      • 15.1.13.2 Products offered
      • 15.1.13.3 Recent developments
        • 15.1.13.3.1 Product launches and approvals
        • 15.1.13.3.2 Deals
        • 15.1.13.3.3 Other developments
    • 15.1.14 EMPATICA INC.
      • 15.1.14.1 Business overview
      • 15.1.14.2 Products offered
      • 15.1.14.3 Recent developments
        • 15.1.14.3.1 Product launches and approvals
        • 15.1.14.3.2 Deals
    • 15.1.15 VITALCONNECT
      • 15.1.15.1 Business overview
      • 15.1.15.2 Products offered
      • 15.1.15.3 Recent developments
        • 15.1.15.3.1 Deals
        • 15.1.15.3.2 Other developments
    • 15.1.16 AMETRIS, LLC
      • 15.1.16.1 Business overview
      • 15.1.16.2 Products offered
      • 15.1.16.3 Recent developments
        • 15.1.16.3.1 Deals
    • 15.1.17 ALIVECOR, INC.
      • 15.1.17.1 Business overview
      • 15.1.17.2 Products offered
      • 15.1.17.3 Recent developments
        • 15.1.17.3.1 Product launches and approvals
        • 15.1.17.3.2 Deals
    • 15.1.18 WITHINGS
      • 15.1.18.1 Business overview
      • 15.1.18.2 Products offered
      • 15.1.18.3 Recent developments
        • 15.1.18.3.1 Product launches and approvals
        • 15.1.18.3.2 Deals
    • 15.1.19 VIVALNK, INC.
      • 15.1.19.1 Business overview
      • 15.1.19.2 Products offered
      • 15.1.19.3 Recent developments
        • 15.1.19.3.1 Product launches and approvals
    • 15.1.20 MEDIBIOSENSE
      • 15.1.20.1 Business overview
      • 15.1.20.2 Products offered
      • 15.1.20.3 Recent developments
        • 15.1.20.3.1 Product launches and approvals
  • 15.2 OTHER PLAYERS
    • 15.2.1 SIBEL HEALTH, INC.
    • 15.2.2 BYTEFLIES
    • 15.2.3 STRADOS LABS
    • 15.2.4 ONERA TECHNOLOGIES B.V.
    • 15.2.5 EPICORE BIOSYSTEMS, INC.

16 RESEARCH METHODOLOGY

  • 16.1 RESEARCH APPROACH
    • 16.1.1 SECONDARY RESEARCH
      • 16.1.1.1 Key data from secondary sources
    • 16.1.2 PRIMARY RESEARCH
      • 16.1.2.1 Primary sources
      • 16.1.2.2 Key data from primary sources
      • 16.1.2.3 Breakdown of primary interviews
      • 16.1.2.4 Insights from primary experts
  • 16.2 RESEARCH METHODOLOGY DESIGN
  • 16.3 MARKET SIZE ESTIMATION
  • 16.4 DATA TRIANGULATION
  • 16.5 RESEARCH ASSUMPTIONS
  • 16.6 RESEARCH LIMITATIONS
    • 16.6.1 METHODOLOGY-RELATED
    • 16.6.2 SCOPE-RELATED
  • 16.7 RISK ASSESSMENT

17 APPENDIX

  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 17.3 CUSTOMIZATION OPTIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 EXCHANGE RATES FOR CURRENCY CONVERSION
  • TABLE 2 IMPACT OF PORTER'S FIVE FORCES
  • TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 4 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2025
  • TABLE 5 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION, 2025
  • TABLE 6 IMPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2024 (USD MILLION)
  • TABLE 7 EXPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2024 (USD MILLION)
  • TABLE 8 KEY CONFERENCES AND EVENTS, 2026-2027
  • TABLE 9 CASE 1: CLINICAL GRADE WEARABLE VITAL SIGNS MONITORING IN NEONATAL & MATERNAL TRIALS
  • TABLE 10 CASE 2: MULTI LEAD WEARABLE ECG MONITORING FOR CARDIOLOGY TRIALS
  • TABLE 11 CASE 3: CONTINUOUS RESPIRATORY MONITORING IN CHRONIC LUNG DISEASE
  • TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES
  • TABLE 14 LIST OF PATENTS/PATENT APPLICATIONS
  • TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
  • TABLE 21 KEY BUYING CRITERIA, BY END USER
  • TABLE 22 UNMET NEEDS IN WEARABLES IN PHARMA & BIOTECH MARKET
  • TABLE 23 END-USER EXPECTATIONS IN WEARABLES IN PHARMA & BIOTECH MARKET
  • TABLE 24 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 25 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
  • TABLE 26 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES
  • TABLE 27 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 28 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS
  • TABLE 29 WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 30 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS
  • TABLE 31 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 32 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS
  • TABLE 33 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 34 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES
  • TABLE 35 WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS
  • TABLE 37 WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 38 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS
  • TABLE 39 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 40 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 41 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 42 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION
  • TABLE 44 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE
  • TABLE 46 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION
  • TABLE 48 WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 49 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/STROKE PREVENTION
  • TABLE 50 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/ STROKE PREVENTION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 51 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION
  • TABLE 52 WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY
  • TABLE 54 WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 56 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS
  • TABLE 58 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 59 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 WEARABLES IN PHARMA & BIOTECH MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 WEARABLES IN PHARMA & BIOTECH MARKET FOR LUNG CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 62 WEARABLES IN PHARMA & BIOTECH MARKET FOR PROSTATE CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 63 WEARABLES IN PHARMA & BIOTECH MARKET FOR COLORECTAL CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 64 WEARABLES IN PHARMA & BIOTECH MARKET FOR BRAIN TUMOR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 65 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER SOLID TUMORS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 66 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES
  • TABLE 67 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 68 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 69 WEARABLES IN PHARMA & BIOTECH MARKET FOR LEUKEMIA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 70 WEARABLES IN PHARMA & BIOTECH MARKET FOR LYMPHOMA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 71 WEARABLES IN PHARMA & BIOTECH MARKET FOR MULTIPLE MYELOMA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 72 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER HEMATOLOGIC MALIGNANCIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 73 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES
  • TABLE 74 WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 75 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH
  • TABLE 76 WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 77 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY DISORDERS
  • TABLE 78 WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 79 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT
  • TABLE 80 WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 81 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY
  • TABLE 82 WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 83 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT
  • TABLE 84 WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 85 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN'S HEALTH & REPRODUCTIVE HEALTH
  • TABLE 86 WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN'S HEALTH & REPRODUCTIVE HEALTH, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 87 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES
  • TABLE 88 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 89 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 90 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY
  • TABLE 91 WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 92 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS
  • TABLE 93 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 94 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 95 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS
  • TABLE 96 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 97 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS
  • TABLE 98 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 99 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS
  • TABLE 100 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 101 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT
  • TABLE 102 WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 103 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING
  • TABLE 104 WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 105 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS
  • TABLE 106 WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 107 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 108 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES
  • TABLE 109 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 110 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS
  • TABLE 111 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 112 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS
  • TABLE 113 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 114 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS
  • TABLE 115 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 116 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 117 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 118 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 119 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 120 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 121 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 122 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 123 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 124 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 125 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 126 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 127 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 128 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 129 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 130 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 131 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 132 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 133 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 134 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 135 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 136 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 137 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 138 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 139 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 141 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 142 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 143 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 144 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 145 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 146 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 147 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 148 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 149 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 150 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 151 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 152 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 153 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 154 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 155 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 156 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 157 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 158 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 159 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 160 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 161 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 162 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 163 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 164 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 165 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 166 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 167 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 168 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 169 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 171 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 172 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 173 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 174 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 175 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 176 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 177 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 178 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 179 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 180 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 181 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 182 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 183 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 184 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 185 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 186 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 187 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 188 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 189 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 190 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 191 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 192 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 193 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 194 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 195 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 196 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 197 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 198 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 199 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 200 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 201 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 202 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 203 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 204 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 205 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 206 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 207 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 208 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 219 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 220 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 221 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 222 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 223 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 224 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 225 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 226 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 228 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 229 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 230 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 231 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 232 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 233 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 234 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 235 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 236 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 237 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 238 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 239 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 240 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 241 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 242 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 243 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 244 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 245 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 246 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 247 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 248 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 249 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 250 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 251 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 253 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 254 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 255 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 256 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 257 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 258 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 259 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 260 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 261 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 262 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 263 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 264 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 265 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 266 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 267 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 268 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 269 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 270 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 271 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 272 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 273 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 274 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 275 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 276 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 277 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 278 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 279 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 280 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 281 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 282 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 283 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 284 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 285 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 286 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 287 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 288 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 289 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 290 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 291 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 292 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 293 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 294 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 295 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 296 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 297 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 298 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 299 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 300 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 301 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 302 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 303 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 304 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 305 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 306 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 307 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 308 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 309 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 310 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 311 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 312 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 313 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 314 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 315 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 316 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 317 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 318 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 319 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 320 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 321 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 322 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 323 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 324 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 325 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 326 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 327 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 328 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 329 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 330 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 331 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 332 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 333 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 334 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 335 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 336 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 337 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 338 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 339 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 340 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 341 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 342 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 343 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 344 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 345 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 346 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 347 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 348 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 349 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 350 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 351 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 352 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 353 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 354 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 355 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 356 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 357 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 358 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 359 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 360 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 361 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 362 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 363 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 364 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 365 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 366 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 367 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
  • TABLE 368 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 369 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 370 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 371 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 372 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 373 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 374 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 375 STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLES IN PHARMA & BIOTECH MARKET, 2023-2026
  • TABLE 376 WEARABLES IN PHARMA & BIOTECH MARKET: DEGREE OF COMPETITION
  • TABLE 377 REGION FOOTPRINT
  • TABLE 378 PRODUCT FOOTPRINT
  • TABLE 379 THERAPEUTIC AREA FOOTPRINT
  • TABLE 380 APPLICATION FOOTPRINT
  • TABLE 381 END USER FOOTPRINT
  • TABLE 382 LIST OF START-UPS/SMES
  • TABLE 383 COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • TABLE 384 WEARABLES IN PHARMA & BIOTECH MARKET: PRODUCT LAUNCHES AND APPROVALS, 2023-2026
  • TABLE 385 WEARABLES IN PHARMA & BIOTECH MARKET: DEALS, 2023-2026
  • TABLE 386 WEARABLES IN PHARMA & BIOTECH MARKET: OTHER DEVELOPMENTS, 2023-2026
  • TABLE 387 DEXCOM, INC.: COMPANY OVERVIEW
  • TABLE 388 DEXCOM, INC.: PRODUCTS OFFERED
  • TABLE 389 DEXCOM, INC.: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 390 DEXCOM, INC.: DEALS
  • TABLE 391 ABBOTT: COMPANY OVERVIEW
  • TABLE 392 ABBOTT: PRODUCTS OFFERED
  • TABLE 393 ABBOTT: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 394 ABBOTT: DEALS
  • TABLE 395 ABBOTT: OTHER DEVELOPMENTS
  • TABLE 396 MASIMO: COMPANY OVERVIEW
  • TABLE 397 MASIMO: PRODUCTS OFFERED
  • TABLE 398 MASIMO: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 399 MASIMO: DEALS
  • TABLE 400 BD: COMPANY OVERVIEW
  • TABLE 401 BD: PRODUCTS OFFERED
  • TABLE 402 BD: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 403 BD: DEALS
  • TABLE 404 APPLE INC.: COMPANY OVERVIEW
  • TABLE 405 APPLE INC.: PRODUCTS OFFERED
  • TABLE 406 APPLE INC.: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 407 APPLE INC.: DEALS
  • TABLE 408 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 409 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
  • TABLE 410 BOSTON SCIENTIFIC CORPORATION: DEALS
  • TABLE 411 IRHYTHM TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 412 IRHYTHM TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 413 IRHYTHM TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 414 IRHYTHM TECHNOLOGIES, INC.: DEALS
  • TABLE 415 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 416 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
  • TABLE 417 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 418 KONINKLIJKE PHILIPS N.V.: DEALS
  • TABLE 419 KONINKLIJKE PHILIPS N.V.: OTHER DEVELOPMENTS
  • TABLE 420 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 421 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 422 MEDTRONIC: DEALS
  • TABLE 423 BIOINTELLISENSE, INC.: COMPANY OVERVIEW
  • TABLE 424 BIOINTELLISENSE, INC.: PRODUCTS OFFERED
  • TABLE 425 BIOINTELLISENSE, INC.: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 426 BIOINTELLISENSE, INC.: DEALS
  • TABLE 427 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 428 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 429 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 430 GE HEALTHCARE: COMPANY OVERVIEW
  • TABLE 431 GE HEALTHCARE: PRODUCTS OFFERED
  • TABLE 432 GE HEALTHCARE: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 433 GE HEALTHCARE: DEALS
  • TABLE 434 BIOBEAT: COMPANY OVERVIEW
  • TABLE 435 BIOBEAT: PRODUCTS OFFERED
  • TABLE 436 BIOBEAT: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 437 BIOBEAT: DEALS
  • TABLE 438 BIOBEAT: OTHER DEVELOPMENTS
  • TABLE 439 EMPATICA INC.: COMPANY OVERVIEW
  • TABLE 440 EMPATICA INC.: PRODUCTS OFFERED
  • TABLE 441 EMPATICA INC.: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 442 EMPATICA INC.: DEALS
  • TABLE 443 VITALCONNECT: COMPANY OVERVIEW
  • TABLE 444 VITALCONNECT: PRODUCTS OFFERED
  • TABLE 445 VITALCONNECT: DEALS
  • TABLE 446 VITALCONNECT: OTHER DEVELOPMENTS
  • TABLE 447 AMETRIS, LLC: COMPANY OVERVIEW
  • TABLE 448 AMETRIS, LLC: PRODUCTS OFFERED
  • TABLE 449 AMETRIS, LLC: DEALS
  • TABLE 450 ALIVECOR, INC.: COMPANY OVERVIEW
  • TABLE 451 ALIVECOR, INC.: PRODUCTS OFFERED
  • TABLE 452 ALIVECOR, INC.: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 453 ALIVECOR, INC.: DEALS
  • TABLE 454 WITHINGS: COMPANY OVERVIEW
  • TABLE 455 WITHINGS: PRODUCTS OFFERED
  • TABLE 456 WITHINGS: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 457 WITHINGS: DEALS
  • TABLE 458 VIVALNK, INC.: COMPANY OVERVIEW
  • TABLE 459 VIVALNK, INC.: PRODUCTS OFFERED
  • TABLE 460 VIVALNK, INC.: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 461 MEDIBIOSENSE: COMPANY OVERVIEW
  • TABLE 462 MEDIBIOSENSE: PRODUCTS OFFERED
  • TABLE 463 MEDIBIOSENSE: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 464 SIBEL HEALTH, INC.: COMPANY OVERVIEW
  • TABLE 465 BYTEFLIES: COMPANY OVERVIEW
  • TABLE 466 STRADOS LABS: COMPANY OVERVIEW
  • TABLE 467 ONERA TECHNOLOGIES B.V.: COMPANY OVERVIEW
  • TABLE 468 EPICORE BIOSYSTEMS, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 MARKET SCENARIO
  • FIGURE 2 GLOBAL WEARABLES IN PHARMA & BIOTECH MARKET, 2024-2031
  • FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLES IN PHARMA & BIOTECH MARKET
  • FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF WEARABLES IN PHARMA & BIOTECH MARKET
  • FIGURE 5 HIGH-GROWTH SEGMENTS IN WEARABLES IN PHARMA & BIOTECH MARKET
  • FIGURE 6 ASIA PACIFIC TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD
  • FIGURE 7 EXPANSION OF DECENTRALIZED AND REMOTE PATIENT-CENTRIC TRIALS TO DRIVE MARKET
  • FIGURE 8 PHARMACEUTICAL & BIOTECH COMPANIES AND US ACCOUNTED FOR LARGEST SHARES IN 2025
  • FIGURE 9 INDIA TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD
  • FIGURE 10 PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 11 SUPPLY CHAIN ANALYSIS
  • FIGURE 12 ECOSYSTEM ANALYSIS
  • FIGURE 13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 15 PATENT PUBLICATION TRENDS, 2015-2026
  • FIGURE 16 JURISDICTION AND TOP APPLICANT ANALYSIS
  • FIGURE 17 PATENT ANALYSIS
  • FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 19 KEY BUYING CRITERIA, BY END USER
  • FIGURE 20 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT
  • FIGURE 21 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT
  • FIGURE 22 REVENUE ANALYSIS OF KEY PLAYERS, 2021-2025
  • FIGURE 23 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
  • FIGURE 24 BRAND/PRODUCT COMPARISON
  • FIGURE 25 FINANCIAL METRICS (EV/EBITDA)
  • FIGURE 26 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 27 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 28 COMPANY FOOTPRINT
  • FIGURE 29 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025
  • FIGURE 30 DEXCOM, INC.: COMPANY SNAPSHOT
  • FIGURE 31 ABBOTT: COMPANY SNAPSHOT
  • FIGURE 32 MASIMO: COMPANY SNAPSHOT
  • FIGURE 33 BD: COMPANY SNAPSHOT
  • FIGURE 34 APPLE INC.: COMPANY SNAPSHOT
  • FIGURE 35 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • FIGURE 36 IRHYTHM TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 37 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • FIGURE 38 MEDTRONIC: COMPANY SNAPSHOT
  • FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 41 RESEARCH DESIGN
  • FIGURE 42 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 43 BOTTOM-UP APPROACH
  • FIGURE 44 TOP-DOWN APPROACH
  • FIGURE 45 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 46 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 47 DATA TRIANGULATION